SWOG clinical trial number
SWOG-9229

Concurrent Cisplatin, Prolonged Oral Etoposide and Vincristine Plus Chest and Brain Irradiation for Limited Small Cell Lung Carcinoma, Phase II Pilot

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Concurrent Cisplatin, Prolonged Oral Etoposide and Vincristine Plus Chest and Brain Irradiation for Limited Small Cell Lung Carcinoma, Phase II Pilot
Activated
02/15/1993
Closed
05/01/1994

Research committees

Lung Cancer

Publication Information Expand/Collapse

1998

Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: A phase II study of the Southwest Oncology Group (SWOG-9229).

CR Thomas Jr;DJ Giroux;KJ Stelzer;JB Craig;LR Laufman;SA Taylor;JW Goodwin;JJ Crowley;RB Livingtson Int J Radiat Oncol Biol Phys 40(5):1039-1047

1995

Concurrent cisplatin (CDDP), prolonged oral etoposide (E) and vincristine (VCR) plus chest and brain irradiation (RT) induction therapy for limited-stage small cell lung carcinoma (SCLC): Preliminary report of a Southwest Oncology Group study (SWOG-9229)

CR Thomas Jr;DJ Rector;KJ Stelzer;RB Livingston ASCO 14:363(#1111)

Other Clinical Trials

SWOG Clinical Trial Number
A082302

EVALUATING ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS TO PREVENT RECURRENCE IN STAGE I NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE III TRIAL (AASI-NSCLC)
Research Committee(s)
Lung Cancer
Activated
03/02/2027
Open
SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase